Skip to content

Study · Observational study · n = 169,768 · 2025

5 results

Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi-institutional propensity score-matched study.

Wu JY, Chan SE, Hsu WH, Kuo CC, Tsai YW, Liu TH, Huang PY, Chuang MH, Yu T, Lai CC

Diabetes, obesity & metabolism20 Mar 2025Cited by 13 (Europe PMC)

PMID40109063 (opens in a new tab)DOI10.1111/dom.16353 (opens in a new tab)PepBankPUB-40109063
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In propensity-matched adults with obesity, tirzepatide was associated with a lower risk of all-cause mortality than bariatric metabolic surgery (HR 0.311).

    In plain wordsIn matched adults with obesity, people on tirzepatide were linked to a lower risk of death from any cause than people who had bariatric surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause mortality
    Study

    n = 169,768

    Comparator
    Bariatric metabolic surgery
    Analysis
    Primary
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.311 ratio
    tirzepatide vs BMS
    Incidence of all-cause mortality
    0.19 per 100 person-years
    tirzepatide
    Incidence of all-cause mortality
    0.57 per 100 person-years
    BMS

    Source sentences

    Summary
    Tirzepatide was associated with a significantly lower risk of all-cause mortality compared with BMS (HR, 0.311; 95% CI, 0.257-0.375; p < 0.0001).
    3 context sentences
    Summary · context
    The incidence of all-cause mortality was 0.19 per 100 person-years in the tirzepatide group compared with 0.57 in the BMS group.
    Summary · context
    This retrospective cohort study used the TriNetX network to identify adults with a body mass index (BMI) ≥ 30 kg/m2.
    Summary · context
    Patients initiating tirzepatide treatment were compared with those undergoing BMS.
  2. 02HumanObservational studyEfficacy outcome

    In propensity-matched adults with obesity, tirzepatide was associated with a lower risk of MACEs than bariatric metabolic surgery (HR 0.743).

    In plain wordsIn matched adults with obesity, people on tirzepatide were linked to fewer major heart and vessel events than people who had bariatric surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse cardiovascular events (MACEs)
    Study

    n = 169,768

    Comparator
    Bariatric metabolic surgery
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.743 ratio
    tirzepatide vs BMS

    Source sentences

    Summary
    Tirzepatide also reduced the risk of MACEs (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001) and MAKEs (HR, 0.375; 95% CI, 0.336-0.419; p < 0.0001).
    2 context sentences
    Summary · context
    This retrospective cohort study used the TriNetX network to identify adults with a body mass index (BMI) ≥ 30 kg/m2.
    Summary · context
    Patients initiating tirzepatide treatment were compared with those undergoing BMS.
  3. 03HumanObservational studyEfficacy outcome

    In propensity-matched adults with obesity, tirzepatide was associated with a lower risk of MAKEs than bariatric metabolic surgery (HR 0.375).

    In plain wordsIn matched adults with obesity, people on tirzepatide were linked to fewer major kidney events than people who had bariatric surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse kidney events (MAKEs)
    Study

    n = 169,768

    Comparator
    Bariatric metabolic surgery
    Analysis
    Secondary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.375 ratio
    tirzepatide vs BMS

    Source sentences

    Summary
    Tirzepatide also reduced the risk of MACEs (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001) and MAKEs (HR, 0.375; 95% CI, 0.336-0.419; p < 0.0001).
    2 context sentences
    Summary · context
    This retrospective cohort study used the TriNetX network to identify adults with a body mass index (BMI) ≥ 30 kg/m2.
    Summary · context
    Patients initiating tirzepatide treatment were compared with those undergoing BMS.
  4. 04HumanObservational studyEfficacy outcome

    In propensity-matched adults with obesity, the lower mortality with tirzepatide than with bariatric metabolic surgery was consistent across age groups, genders and BMI categories.

    In plain wordsIn matched adults with obesity, the link between tirzepatide and lower death risk than surgery held across age, sex and BMI groups.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause mortality across age, sex and BMI subgroups
    Study

    n = 169,768

    Comparator
    Bariatric metabolic surgery
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mortality benefits were consistent across age groups, genders and BMI categories.
    2 context sentences
    Summary · context
    This retrospective cohort study used the TriNetX network to identify adults with a body mass index (BMI) ≥ 30 kg/m2.
    Summary · context
    Patients initiating tirzepatide treatment were compared with those undergoing BMS.
  5. 05HumanObservational studyEfficacy outcome

    In propensity-matched adults with obesity, stratified analyses showed significant reductions in mortality, MACEs and MAKEs with tirzepatide versus bariatric metabolic surgery across most categories.

    In plain wordsIn matched adults with obesity, tirzepatide was linked to lower risks than surgery across most subgroups.

    Peptide
    Tirzepatide
    Outcome
    DecreasePrimary and secondary outcomes in stratified analyses
    Study

    n = 169,768

    Comparator
    Bariatric metabolic surgery
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Stratified analyses demonstrated significant reductions in primary and secondary outcomes across most categories.
    2 context sentences
    Summary · context
    This retrospective cohort study used the TriNetX network to identify adults with a body mass index (BMI) ≥ 30 kg/m2.
    Summary · context
    Patients initiating tirzepatide treatment were compared with those undergoing BMS.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.